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Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic 
neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 
protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of 
Parkinson's disease. Increasing endogenous FGF20 production might provide a less-invasive, 
more translational way of providing such protection. Accordingly, we adopted a targeted 
repositioning approach to screen for candidate FDA-approved drugs with potential to 
enhance endogenous FGF20 production in brain. In silico interrogation of the Broad 
Institute’s Connectivity Map database (CMap), revealed 50 candidate drugs predicted to 
increase FGF20 transcription, 16 of which had profiles favourable for use in Parkinson’s 
disease. Of these, 11 drugs were found to significantly elevate FGF20 protein production in 
MCF-7 cells, between two- and four-fold. Four drugs were selected for examination in vivo. 
Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or 
trazodone, significantly elevated FGF20 levels in the nigrostriatal tract. Preliminary 
examination in the unilateral 6-hydroxydopamine-lesioned rat revealed a modest but 
significant protection against nigral cell loss with both drugs. Our data demonstrate the 
power of targeted repositioning as a method to identify existing drugs that may combat 
disease progression in Parkinson’s by boosting FGF20 levels.  
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1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder characterised by motor symptoms 
such as tremor, bradykinesia and postural instability 1. These symptoms largely result from 
degeneration of dopaminergic neurones in the substantia nigra pars compacta (SNc). 
Current pharmacological treatments, which mostly replenish the lost dopamine (e.g. L-
DOPA), provide some relief of the motor symptoms. However, these treatments do not 
combat the underlying dopaminergic neurodegeneration, so the disease pathology and 
associated symptoms progress and remain a significant problem. There remains a clear need 
for treatments that might slow or halt disease progression. Given the pathogenesis of PD is 
wide-ranging 2 and syndrome-like 3, interfering with individual mechanisms has yet to yield 
success. A more fruitful approach to providing neuroprotection might be to use 
neurotrophic factors to enhance the survival of the vulnerable neurones exposed to such 
multiple insults.  
Fibroblast growth factor 20 (FGF20) is a possible candidate for providing neuroprotection in 
PD. FGF20 is a brain-specific factor that is abundant in the nigrostriatal pathway where it 
plays a role in dopamine neurone development, maintenance and survival 4,5. Addition of 
exogenous FGF20 has been shown to protect cultured dopaminergic neurones from toxic 
insults including glutamate and the dopaminergic toxin, 6-hydroxydopamine (6-OHDA) 4,6. 
Furthermore, we found that supra-nigral infusion of recombinant human FGF20 (rhFGF20) 
protected against dopaminergic neurone degeneration and preserved motor function in 
both full and partial 6-OHDA lesion rat models of PD 6,7.  
While the approach of using neurotrophic factors therapeutically in PD has maintained 
traction, the failure to demonstrate efficacy in clinical trials is disappointing 8,9. Clinical 
progress may have been hampered due to the reliance on direct intracerebral delivery, 
insufficient distribution and the targeting of a single site - dopaminergic terminals in the 
striatum – from where retrograde transport back to the substantia nigra may be limited by 
impaired axonal transport and signalling in PD 10-13. Finding alternative ways of increasing 
trophic factor levels in the brain might overcome these hurdles. A recent study 
demonstrated that ultrasonography-guided rhFGF20 proteoliposomes can provide 
protection in the 6-OHDA lesioned rat when delivered systemically, avoiding the need for 
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direct intracerebral delivery 14.  As an alternative approach, we explored the possibility of 
therapeutically driving endogenous FGF20 production rather than relying on direct infusion 
of an exogenous supply.  
We recently identified GFAP-positive astrocytes as a source of FGF20 within the substantia 
nigra 7. Given these cells are spared in PD 15,16, they provide a potential source from which to 
boost production of endogenous FGF20. In order to find suitable drugs to achieve this, we 
have undertaken a novel, targeted repositioning approach using a combination of 
bioinformatics, in vitro and in vivo assays. Specifically, we interrogated the transcriptional 
profiles of more than a thousand Food and Drug Administration (FDA)-approved drugs from 
the Broad Institute’s connectivity mapping database 17 to identify drugs that increase FGF20 
gene transcription. We selected those that cross the blood-brain barrier, have no contra-
indication for use in PD and for their ability to boost endogenous FGF20 protein production 
in vitro. A sub-set of the most promising drugs progressed through to in vivo studies to 
determine FGF20 production in relevant brain regions. Finally, we explored the protective 
efficacy of the best two drugs in a preliminary study in the partial 6-OHDA lesion rat model 
of PD, to generate proof of concept for our targeted repositioning approach. This approach 
revealed salbutamol and triflusal as the two most promising drugs of interest. 
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2. Material and Methods 
2.1 Bioinformatics screening to draw up a shortlist of potential FGF20 boosting 
drugs  
In silico screening involved interrogation of the connectivity map (CMap) from the Broad 
Institute 17 for drugs that increase FGF20 transcription. The CMap consists of the gene 
expression profiles gathered from three human cancer cell lines (MCF-7, PC3 and HL60) for 
1261 drug-like compounds. Robust profiles were defined as previously described 18. Briefly, 
the gene expression change ranks, defined as = 1 − 2 ோିோ೘೔೙ோ೘ೌೣିோ೘೔೙ , where R is the rank of a 
given gene’s expression change (ܴ௠௔௫ being the highest and ܴ௠௜௡ being the lowest ranks), 
were averaged over replicates, ignoring cell type, and filtered based on significance using a 
one sample student’s t-test. Drug candidates for the up-regulation of FGF20 were ranked 
based on the average expression rank of FGF20 in the given drug’s CMAP profile. The top 50 
ranking compounds were subject to further literature-based scrutiny to rule out drugs with 
low blood-brain barrier (BBB) penetration probability, with anticipated contraindications for 
use in PD or with the known emergence of toxicity following chronic dosing.  
 
2.2 Assessment of FGF20 production in MCF-7 cells or ventral mesencephalic 
(VM) primary cultures following treatment with selected drugs  
MCF-7 human breast carcinoma cells (Sigma) were utilised for the initial drug screen to 
maintain consistency with the cells used to generate the transcriptional profiles in the CMap 
database. MCF-7 cells were maintained in DMEM-Glutamax media with 10% foetal bovine 
serum (FBS), 100 μg/ml streptomycin and 100 units/ml penicillin (1% penstrep, Gibco) at 
37°C in 5% CO2. Cells were incubated (~250,000 viable cells per well) in a 6-well plate for 24 
h at 37°C in 5% CO2. Cells were then incubated in FBS-free DMEM-Glutamax medium 
containing 10 µM of candidate drug for a further 24h. This concentration was chosen for 
consistency with that used for the transcriptional profiling. Each drug and respective vehicle 
was tested on a minimum of three independent cultures.  After washing with phosphate-
buffered saline (PBS), cells were detached with 0.25% trypsin for 5 min at 37°C before lysing 
by freeze-thawing and high-frequency sonication in lysis buffer. After centrifugation (10,000 
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rpm for 5 min at 4°C), sample lysates were diluted in dH20 to 1mg/ml protein using a 
standard bicinchoninic acid (BCA) assay, in preparation for FGF20 quantification.   
E13.5 timed-pregnant female Sprague-Dawley rats (Envigo; n=3) were killed with an 
overdose of sodium pentobarbital (200mg, i.p.) and cervical dislocation and the embryos 
(10-15 per litter) removed. Ventral mesencephalic (VM) brain tissue was dissected out, 
pooled for a given litter and washed thrice in ice-cold PBS before incubating in 1 ml 0.25% 
trypsin in PBS at 37°C for 10 min. 9 ml of DMEM Glutamax media with 10% FBS and 1% 
penstrep was added and the cell suspension centrifuged for 5 min at 5000 rpm. The pellet 
was resuspended in 1 ml of fresh medium and triturated to achieve a single cell suspension. 
Trypan blue excluding, viable cells were plated (300,000 cells per coverslip) onto sterile 13 
mm diameter poly-D-lysine coated glass coverslips within a 24-well plate. Cultures were 
incubated in 10% FBS-containing medium at 37oC in a humidified atmosphere of 5% CO2. At 
3 days in-vitro (DIV3), media was aspirated and fresh media added. At 6 days in-vitro (DIV6), 
cells were washed twice with PBS then incubated for 24 h with either vehicle or one of five 
drugs of choice diluted in FBS-free medium before cells were lysed as described above. 
Given that the VM cultures were used to confirm FGF20 production in a physiologically-
relevant cell system, but the effective concentrations would not help inform the doses 
selected for in-vivo studies, we again examined each drug at a single concentration, 
consistent with that used in the MCF-7 cells (10 µM).  
Total FGF20 content within the MCF-7 and VM cell lysates was measured by sandwich 
enzyme-linked immunosorbent assay (ELISA) kits (Cusabio, CSB-EL008626HU). Samples were 
processed, in duplicate, according to the supplier’s protocol. ELISAs were repeated (three 
technical replicates) to ensure reliable findings.   
2.3 Animals 
All in-vivo studies were performed in accordance with the UK Animals Scientific Procedures 
Act (1986) and were approved by King’s College London Animal Welfare and Ethical Review 
Body. A total of 120 adult male Sprague Dawley rats (250-280g; Charles River, UK) were 
used: 80 for the in-vivo screening and 40 for the 6-OHDA neuroprotection study. All animals 
were maintained on a 12:12 hour light:dark cycle with food and water available ad libitum. 
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2.4 Assessment of FGF20 production in brain regions of interest in rats treated 
with selected drugs  
Four drugs were taken through to the in vivo examination: dimethadione, salbutamol, 
trazodone and triflusal. For each drug study, adult male Sprague Dawley rats (250-280g) 
were randomly allocated to receive either vehicle or one of three doses (n=5 per group). 
Within each study, the operator was blinded to the treatment. Treatment was given for 7 
days, via oral gavage according to the following scheme. Dimethadione study: vehicle 
(saline), 10, 30 or 100 mg/kg once daily; salbutamol study: vehicle (saline), 0.5, 5 or 50 
mg/kg twice daily; trazodone study: vehicle (saline), 10, 30 or 50 mg/kg twice daily; trifusal 
study: vehicle (7.2mM HNaCO3; pH7.4), 3, 10 or 30 mg/kg once daily. The dose ranges were 
determined by cross-analysis of existing literature, toxicity and pharmacokinetic data.  
Within 2 h of the last dose, animals were killed by overdose of sodium pentobarbital 
(200mg, i.p.) and the brain rapidly removed. The VM (containing the substantia nigra (SN)) 
and the striatum were dissected out and snap-frozen on dry ice. Tissues were then 
homogenised on ice, via high frequency sonication in 500 µl RIPA lysis buffer (Thermo Fisher) 
containing protease and phosphatase inhibitors (Roche). Neat homogenates were 
centrifuged (10,000 rpm) at 4°C for 5 min before measurement of supernatant protein 
content via BCA assay. Samples were diluted to 1 mg/ml protein with dH2O before 
determination of FGF20 protein levels via ELISA, as described above. 
 
2.5 Examination of the neuroprotective potential of two FGF20 boosting drugs in 
the 6-OHDA partial lesion rat model of Parkinson’s disease  
Drug treatment and 6-OHDA lesioning  
The two most promising drugs from the in vivo screen (salbutamol and triflusal) were taken 
through to this preliminary neuroprotective study. A total of 40 rats were randomly assigned 
to four treatment groups (n=10 per group). Rats were then dosed by oral gavage in an 
operator-blinded manner either twice-daily (9 am and 6 pm) with salbutamol (50 mg/kg) or 
salbutamol vehicle or once-daily (9 am) with triflusal (10 mg/kg) or triflusal vehicle. Doses 
were selected from the dose-range study in 2.4, above. Dosing commenced (in a randomised 
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block design to reduce daily bias between treatment groups) 2 days before induction of a 
partial 6-OHDA-induced lesion and continued daily for 7 days post-lesion. This dosing 
regimen was selected to maximise our chances of achieving neuroprotection by priming 
enhanced FGF20 production prior to introduction of the toxin as well as driving production 
during lesion development. For 6-OHDA lesioning, following anaesthesia induction (5% 
isofluorane/oxygen), animals were placed in a stereotaxic frame with blunt ear bars. 
Anaesthesia was maintained at 3% isofluorane/oxygen and body temperature maintained at 
37°C. The surgical site was sterilised with 0.4% chlorhexidine (Hibiscrub) before making an 
antero-proximal incision along the scalp. Fine-bore holes (Ø 0.5 mm) were made in the skull 
at coordinates AP: +0.2 mm and ML: +3.0 mm (relative to bregma and skull surface) through 
which a blunt-ended 30-gauge needle was inserted to DV: -5.5 mm. 6-OHDA.HBr (12 μg in 3 
μl 0.02% ascorbate/saline) was infused unilaterally into the striatum (0.5 μl/min) and the 
needle withdrawn 5 min later. After suturing, animals received a single dose of 
buprenorphine (Vetergesic; 0.1 mg/kg; s.c.) for analgesia and 1 ml of rehydrating Hartmann’s 
solution was administered s.c. daily for 7 days. Two animals, later identified as allocated to 
the triflusal group, failed to recover adequately from surgery so were excluded from the 
study. 
Immunohistochemical assessment of SNc lesion size 
On post-lesion day 7, animals were killed (2 h post final drug treatment) with an overdose of 
anaesthetic (200mg sodium pentobarbital) before removal of the brains. The mid-brain 
containing the SN was submerged in 4% paraformaldehyde for 24 hours. Fixed brains were 
then embedded in paraffin wax.  Serial 7µm sections of the SN were obtained and processed 
for tyrosine hydroxylase (TH) staining as previously described 7. Photomicrographs of TH-
immunostained SNc sections (n=3 per rat at each of the caudal [AP: -6.0mm], medial [AP: -
5.3mm] and rostral [AP: -4.8mm] levels) were acquired at 20× magnification using a Zeiss 
fluorescent microscope and Axiovision software (Carl Zeiss Ltd). ImageJ software was used to 
manually count viable (i.e. intact round cells with a clear nucleus and cytoplasm) TH-positive 
A9 dopaminergic cells of the SNc in both the lesioned and intact hemispheres. SNc cell 
number in the lesion hemisphere was calculated a percentage of that remaining in the intact 
hemisphere. Data were combined across all three rostro-caudal levels to generate a single 
average value for each animal. Mean data were then calculated per treatment group.  
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2.6 Statistical analyses 
All statistical analyses were performed using GraphPad Prism (version 7). FGF20 protein 
levels in MCF-7 cells were compared between each drug and respective vehicle using a 
Student’s t-test. FGF20 protein levels in VM cell lysates were compared between each drug 
and shared vehicle using a one-way ANOVA with Dunnett’s post-hoc test. Similarly, FGF20 
levels in striatal or VM homogenates from rat brain were compared between any dose of 
drug and vehicle using a one-way ANOVA with Dunnett’s post-hoc test. Differences in nigral 
TH-positive cell counts were compared between drug and vehicle-treated animals using 
Student’s t-tests.  
 
3. Results 
3.1 Bioinformatics screening to draw up shortlist of potential FGF20 boosting 
drugs  
Of the top 50 ranking drugs identified through interrogation of the CMap database to 
increase FGF20 gene transcription, a number were eliminated due to low BBB penetration 
probability (e.g. sulconazole, cefsulodin and ketanserin). Other drugs were eliminated owing 
to contraindications for use in PD (e.g. antipsychotic drugs, pimozide and fluspirilene) or 
known toxicity associated with chronic use (e.g. flunixin) (listed in Supplementary Table S1 
online). Sixteen drugs of interest remained: these came from a wide range of 
pharmacological classes and are, or have been, used for many different conditions (Table 1). 
All sixteen were taken forward into in-vitro investigations of FGF20 protein production.  
3.2 Effects of shortlisted drugs on FGF20 production in MCF-7 cells and VM 
primary cultures 
Absolute basal levels of FGF20 varied between MCF-7 cell cultures, ranging in vehicle-
treated groups from 8 to 28 pg/ml. For this reason, FGF20 protein levels were standardised 
in vehicle-treatment groups between cultures and the drug effects expressed thereafter as 
fold-increase in expression. When testing the 16 drugs on MCF-7 cells, 11 significantly 
elevated FGF20 protein levels compared to their respective vehicles (Table 2): the four most 
significant (dimethadione, salbutamol, trazodone and triflusal) were selected for further 
testing on primary VM cultures. Although propranolol looked promising in terms of 
significance of FGF20 protein elevation, it was omitted from further examination at this 
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stage in light of emerging data linking its use to the enhanced risk of PD 19.  
All four selected drugs significantly elevated FGF20 levels in VM cultures compared to 
vehicle (Fig. 1). Basal FGF20 levels obtained from the VM culture screens were more 
consistent between cultures therefore data could be represented as raw values. Fold-
changes were of similar magnitude to those seen in MCF-7 cells: between 2 and 4-fold 
increases compared to vehicle. Although not quantified, visual inspection of the cells prior to 
lysis, revealed healthy looking cells, with no obvious signs of loss of cell viability.  All four 
drugs were accordingly taken through for in-vivo examination of FGF20 production. 
3.3 Effects of selected drugs on FGF20 production in naıv̈e rats 
Although dimethadione displayed a trend towards increasing FGF20 within the striatum and 
VM, neither it nor trazodone significantly elevated endogenous FGF20 in either the striatum 
or VM following 7 days’ dosing in rats (Fig. 2a+b). In contrast, salbutamol (100 mg/kg) 
significantly increased striatal endogenous FGF20 levels 1.7-fold over vehicle treatment 
(one-way ANOVA with Dunnett’s post hoc test, p=0.037; Fig. 2c). Triflusal (10 mg/kg) 
similarly increased striatal FGF20 1.6-fold over vehicle treatment; one-way ANOVA with 
Dunnett’s post hoc test, p=0.008), but also produced a significant increase within the VM 
(1.8-fold over vehicle treatment; one-way ANOVA with Dunnett’s post hoc test, p=0.044) at 
30 mg/kg (Fig. 2d). Having confirmed the ability of salbutamol and triflusal to significantly 
elevate FGF20 levels in vivo, these drugs were next examined for neuroprotective potential. 
3.4 Preliminary examination of the neuroprotective potential of the FGF20 
boosting drugs, salbutamol and triflusal, in unilaterally 6-OHDA-lesioned rats 
Both salbutamol and triflusal displayed neuroprotective efficacy in this partial 6-OHDA-
lesioned rat model of PD. Representative photomicrographs taken from the medial level of 
the SNc show increased cells in the lesion hemisphere from salbutamol-treated (Fig. 3a) or 
triflusal-treated (Fig. 3c) animals when compared to their respective vehicle-treated 
controls. Although manual rather than the more comprehensive stereological analysis was 
performed, studies comparing these two modes of counting in the 6-OHDA model have 
found no significant difference in the outcome between these measures, supporting the 
validity of our analysis 20. Furthermore, the mean number of cells counted in the intact 
hemisphere per section was consistent with previous reports by this and other groups of 
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around 100 cells 20,21: 109.4 ± 2.6 in salbutamol vehicle group; intact: 104.0 ± 6.5 in 
salbutamol treatment group; 100.6 ± 8.7 in triflusal vehicle group; 97.3 ± 8.2 in triflusal 
treatment group. Across the extent of the SNc, salbutamol increased the percentage of SNc 
cells remaining in the lesioned hemisphere relative to the intact hemisphere from 59.9% ± 
4.1 (n=10) in vehicle-treated animals to 73% ± 4.5 (n=10) (p<0.05; Fig. 3b). Similarly, triflusal 
administration increased SNc cells in the lesioned hemisphere from 63.5% ± 2.6 of intact 
hemisphere in vehicle-treated animals (n=10) to 77.6% ± 1.6 (n=8) (p<0.01; Fig. 3d).  
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4. Discussion 
 
This study set out to explore whether existing drugs could be used to increase endogenous 
FGF20 production in the nigrostriatal tract, rather than relying on direct intracerebral 
infusion of recombinant FGF20. To do so we employed a targeted repositioning strategy, a 
top-down method whereby the target protein of interest was firstly identified, in this case 
FGF20, before subsequent computational, transcriptomic and literature-based mining was 
used to generate a shortlist of compounds. Protein quantification assays were then 
conducted to further filter out candidates that did not increase endogenous FGF20 levels 
before, finally, candidates were tested in a small-scale neuroprotection study. Results of this 
final stage revealed two drugs worthy of future investigation as neuroprotective agents in PD 
– salbutamol and triflusal.  
The targeted repositioning strategy was conducted in a step-wise manner, starting with in 
silico screening to interrogate the CMap transcriptional database. Using the SPIEDw 
algorithm 18,22, a long-list of 50 FDA-approved drugs boosting FGF20 gene transcription in 
human breast carcinoma cells was obtained. Following literature-based mining to identify 
and hence remove any compounds that were known to not cross the BBB, present toxicity 
following chronic use or be contraindicated for use in people with Parkinson’s, 16 drugs of 
interest remained. These were screened for the ability to boost FGF20 protein production in 
vitro. Although the initial MCF-7 cell line of choice bears no resemblance to PD-relevant 
cells, their use was deliberate for two reasons. Firstly, since these cells had been used to 
populate the CMap transcriptional database, discovering that 11 of the 16 drugs tested 
significantly elevated FGF20 production in these cells (between 2 and 4.5-fold), generated 
confidence in the translational potential between the gene expression changes and 
accomplished protein production. Secondly, selecting those drugs that proved most effective 
in the MCF-7 cells, enabled restriction of the number that progressed through to primary 
cultures, thereby ensuring NC3R compliance.  
All four drugs taken into VM cultures increased FGF20 production. These mixed neuronal 
and glial cultures were ideal for our purposes, since FGF20 appears to be made not in 
dopaminergic neurones themselves, but rather in astrocytes and other, as yet unidentified 
cells 7. The efficacy of the drugs was similar in VM cultures as was observed in the MCF-7 
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cells in terms of fold-increase in FGF20 levels, suggesting the molecular mechanisms 
underpinning the increased transcription and translation are likely similar between the two 
different cell systems.  
Given the significant increases noted in the VM cultures, all four drugs progressed through 
to in vivo examination. Doses selected for investigation were in line with those used in 
previous unrelated rodent studies and fell significantly below known LD50 values 23-26. 
Although both dimethadione and trazodone produced some elevation in FGF20 protein 
levels, these failed to reach significance. While they were not taken further in the present 
study, given the strength of their effects in vitro, these drugs remain of interest. Indeed, 
these initial in vivo studies were conducted with small sample sizes, so false negatives 
cannot be ruled out. Salbutamol and triflusal both significantly elevated FGF20 protein 
levels. Salbutamol increased FGF20 in the striatum but not within the VM, while triflusal 
increased FGF20 in both the striatum and VM (containing SNc). Given we have 
demonstrated FGFR1, 3 and 4 expression on TH-positive cells in the SNc and FGFR1 
expression on striatal TH-positive terminals7, elevating FGF20 levels in either the striatum or 
the SNc has the potential to impact on the survival of dopaminergic neurones. The cellular 
source of elevated FGF20 is still subject to ongoing investigation. Astrocytes have already 
been identified as a key source in the SNc 7 and our recent findings support astrocytes being 
a source of FGF20 in the striatum too (see Supplementary Fig. S2 online). Nevertheless, 
FGF20 co-localises with at least one other type of non-dopaminergic cell 7, that could act as 
an additional, potential source of production and ongoing studies will help to identify this.    
Of note, there was a decline in striatal FGF20 production at the highest doses of triflusal. The 
reason behind this remains to be determined but the possibility of receptor desensitisation 
will need to be considered when further exploring the effective dose range. 
As a final check on the validity of this repositioning process to locate drugs of interest to 
provide neuroprotection in PD, a small-scale neuroprotection study was conducted.  
Following a week of treatment, both salbutamol and triflusal were able to provide modest, 
but significant protection to SNc cells in a 6-OHDA rat model of PD. Given the mild size of 
lesion, we were not able to examine for behavioural improvements using cylinder and 
adjusted stepping tests. This is something that will require addressing in the future in 
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animals bearing a larger nigrostriatal tract lesion in order to confirm functionality of the 
protected neurones.    
Since commencing this work in early 2017, two of the four candidates that progressed into 
our in vivo stage have been published as contenders for therapies targeting 
neurodegenerative diseases. The first of these is the β-adrenergic receptor agonist 
salbutamol 19, a commonly used drug for asthma and COPD. Mittal et al suggest salbutamol’s 
protective mechanism relates to the downregulation of SNCA gene transcription and that 
this is directly related to the adrenergic activity of the compound. Mittal et al further report 
that salbutamol lowers risk of PD incidence in a large-scale epidemiological analysis of a 
Norwegian population whilst propranolol, a non-selective β-adrenergic receptor antagonist, 
increases risk (hence it being withdrawn from further investigation in the present study). 
Similar benefits and risks of salbutamol and propranolol have been recently supported by 
some 27, but not other 28 independent reports. Although we too suggest salbutamol as a 
potential protective therapy for PD, we have identified a distinct mechanism, that of 
increased endogenous FGF20 transcription within PD-relevant tissues. We propose these 
two mechanisms may work together to provide neuroprotection in PD, although further 
studies utilising FGFR antagonists are required to confirm the involvement of FGF20 in 
salbutamol’s action.  
The second drug highlighted by others is the antidepressant, trazodone 29. Halliday et al 
identified trazodone as a drug that would reduce the phosphorylated alpha-subunit of 
eukaryotic initiation factor 2 (eIF2α-P), an initiation factor found at high levels within the 
brains of people with PD and other neurodegenerative diseases 30. Its presence is linked with 
the deposition of phosphorylated tau 31 and its over activation has shown to cause 
degeneration and synapse degradation 32. Interestingly trazodone presents α1- and α2-
adrenergic receptor antagonism 33, highlighting the potential interaction of the adrenergic 
system and neuroprotection. Although trazodone enhanced FGF20 production within our 
cell screens it did not within our in vivo tests. It will therefore be of interest to understand 
whether trazodone is neuroprotective through this eIF2α-P mechanism, and whether 
trazodone retains efficacy in the proposed future human trials. 
To summarise, we previously reported that direct intracerebral infusion of FGF20 is 
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neuroprotective in the partial and full 6-OHDA lesioned rat model of PD 6. We now 
demonstrate that we can boost endogenous brain levels of FGF20 using drugs originally 
identified from in silico screening of transcriptional databases and subsequently screened 
through a reductionist approach in vitro and then in vivo. Two of these drugs, salbutamol 
and triflusal, afforded significant protection against 6-OHDA lesioning in a mild 6-OHDA 
lesion model of PD. Current studies are underway to more thoroughly investigate the 
neuroprotective potential of salbutamol and triflusal and to identify the potential 
mechanisms involved in enhancing FGF20 gene transcription. 
In conclusion, the work presented here highlights the potential of targeted repositioning as a 
valid strategy to identify drugs that can affect target-gene transcription and, ultimately, 
protein production in PD. By adopting such a repositioning strategy, any promising drugs 
identify have the potential to progress into clinical trials with a shorter lead in time given the 
safety and tolerability is already established. Having validated this targeted approach, the 
opportunity now exists to apply the strategy to other proteins of interest in PD and beyond.  
5. Data Availability 
All data generated or analysed during this study are included in this published article (and its 
Supplementary Information files) or available from the corresponding author on reasonable 
request. 
 
6. References  
1 Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055-2066, 
doi:10.1016/S0140-6736(09)60492-X (2009). 
2 AlDakheel, A., Kalia, L. V. & Lang, A. E. Pathogenesis-targeted, disease-modifying 
therapies in Parkinson disease. Neurotherapeutics 11, 6-23, doi:10.1007/s13311-013-
0218-1 (2014). 
3 Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson's: a syndrome 
rather than a disease? J Neural Transm (Vienna) 124, 907-914, doi:10.1007/s00702-
016-1667-6 (2017). 
4 Ohmachi, S. et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the 
substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 277, 355-
16 
 
360, doi:10.1006/bbrc.2000.3675 (2000). 
5 Grothe, C. et al. Fibroblast growth factor-20 promotes the differentiation of Nurr1-
overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. 
Neurobiol Dis 17, 163-170, doi:10.1016/j.nbd.2004.07.007 (2004). 
6 Sleeman, I. J., Boshoff, E. L. & Duty, S. Fibroblast growth factor-20 protects against 
dopamine neuron loss in vitro and provides functional protection in the 6-
hydroxydopamine-lesioned rat model of Parkinson's disease. Neuropharmacology 63, 
1268-1277, doi:10.1016/j.neuropharm.2012.07.029 (2012). 
7 Boshoff, E. L., Fletcher, E. J. R. & Duty, S. Fibroblast growth factor 20 is protective 
towards dopaminergic neurons in vivo in a paracrine manner. Neuropharmacology 
137, 156-163, doi:10.1016/j.neuropharm.2018.04.017 (2018). 
8 Marks, W. J., Jr. et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a 
double-blind, randomised, controlled trial. Lancet Neurol 9, 1164-1172, 
doi:10.1016/S1474-4422(10)70254-4 (2010). 
9 Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived 
neurotrophic factor infusion in Parkinson disease. Ann Neurol 59, 459-466, 
doi:10.1002/ana.20737 (2006). 
10 Salvatore, M. F. et al. Point source concentration of GDNF may explain failure of 
phase II clinical trial. Exp Neurol 202, 497-505, doi:10.1016/j.expneurol.2006.07.015 
(2006). 
11 Morrison, P. F., Lonser, R. R. & Oldfield, E. H. Convective delivery of glial cell line-
derived neurotrophic factor in the human putamen. J Neurosurg 107, 74-83, 
doi:10.3171/JNS-07/07/0074 (2007). 
12 Olanow, C. W., Bartus, R. T., Volpicelli-Daley, L. A. & Kordower, J. H. Trophic factors for 
Parkinson's disease: To live or let die. Mov Disord 30, 1715-1724, 
doi:10.1002/mds.26426 (2015). 
13 Hegarty, S. V., Lee, D. J., O'Keeffe, G. W. & Sullivan, A. M. Effects of intracerebral 
neurotrophic factor application on motor symptoms in Parkinson's disease: A 
systematic review and meta-analysis. Parkinsonism Relat Disord 38, 19-25, 
doi:10.1016/j.parkreldis.2017.02.011 (2017). 
14 Niu, J. et al. Efficient treatment of Parkinson's disease using ultrasonography-guided 
rhFGF20 proteoliposomes. Drug Deliv 25, 1560-1569, 
17 
 
doi:10.1080/10717544.2018.1482972 (2018). 
15 Hardman, C. D., Halliday, G. M., McRitchie, D. A., Cartwright, H. R. & Morris, J. G. 
Progressive supranuclear palsy affects both the substantia nigra pars compacta and 
reticulata. Exp Neurol 144, 183-192, doi:10.1006/exnr.1997.6415 (1997). 
16 Tong, J. et al. Low levels of astroglial markers in Parkinson's disease: relationship to 
alpha-synuclein accumulation. Neurobiol Dis 82, 243-253, 
doi:10.1016/j.nbd.2015.06.010 (2015). 
17 Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect 
small molecules, genes, and disease. Science 313, 1929-1935, 
doi:10.1126/science.1132939 (2006).  https://www.broadinstitute.org/cmap/. 
18 Williams, G. SPIEDw: a searchable platform-independent expression database web 
tool. BMC Genomics 14, 765, doi:10.1186/1471-2164-14-765 (2013). 
19 Mittal, S. et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene 
driving risk of Parkinson's disease. Science 357, 891-898, 
doi:10.1126/science.aaf3934 (2017). 
20 Iczkiewicz, J. et al. The RGD-containing peptide fragment of osteopontin protects 
tyrosine hydroxylase positive cells against toxic insult in primary ventral 
mesencephalic cultures and in the rat substantia nigra. J Neurochem 114, 1792-1804, 
doi:10.1111/j.1471-4159.2010.06896.x (2010). 
21 Betts, M. J., O'Neill, M. J. & Duty, S. Allosteric modulation of the group III mGlu4 
receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of 
Parkinson's disease. Br J Pharmacol 166, 2317-2330, doi:10.1111/j.1476-
5381.2012.01943.x (2012). 
22  Williams, G. A searchable cross-platform gene expression database reveals 
connections between drug treatments and disease. BMC Genomics 13, 12, 
doi:10.1186/1471-2164-13-12 (2012). http://www.spied.org.uk/cgi-bin/HGNC-
SPIEDXXX.cgi. 
23 Rodger, I. et al. Maternal rat serum concentrations of dimethadione do not explain 
intra-litter differences in the incidence of dimethadione-induced birth defects, 
including novel findings in foetal lung. Toxicology 326, 142-152, 
doi:10.1016/j.tox.2014.10.014 (2014). 
24 Atli, O. et al. Assessment of trazodone-induced cardiotoxicity after repeated doses in 
18 
 
rats. Hum Exp Toxicol, 960327118769717, doi:10.1177/0960327118769717 (2018). 
25 Amtul, Z., Haque, W. & Cechetto, D. F. Dipyridamole plus Triflusal versus Triflusal 
Alone in Infarct Reduction after Middle Cerebral Artery Occlusion. J Stroke 
Cerebrovasc Dis 27, 1283-1287, doi:10.1016/j.jstrokecerebrovasdis.2017.12.013 
(2018). 
26 Libretto, S. E. A review of the toxicology of salbutamol (albuterol). Arch Toxicol 68, 
213-216 (1994). 
27 Gronich, N. et al. beta2-adrenoceptor agonists and antagonists and risk of 
Parkinson's disease. Mov Disord 33, 1465-1471, doi:10.1002/mds.108 (2018). 
28 Searles Nielsen, S., Gross, A., Camacho-Soto, A., Willis, A. W. & Racette, B. A. beta2-
adrenoreceptor medications and risk of Parkinson disease. Ann Neurol 84, 683-693, 
doi:10.1002/ana.25341 (2018). 
29 Halliday, M. et al. Repurposed drugs targeting eIF2&alpha;-P-mediated translational 
repression prevent neurodegeneration in mice. Brain 140, 1768-1783, 
doi:10.1093/brain/awx074 (2017). 
30 Hoozemans, J. J. et al. Activation of the unfolded protein response in Parkinson's 
disease. Biochem Biophys Res Commun 354, 707-711, 
doi:10.1016/j.bbrc.2007.01.043 (2007). 
31 Nijholt, D. A. T., van Haastert, E. S., Rozemuller, A. J. M., Scheper, W. & Hoozemans, J. 
J. M. The unfolded protein response is associated with early tau pathology in the 
hippocampus of tauopathies. J Pathol 226, 693-702, doi:10.1002/path.3969 (2012). 
32 Moreno, J. A. et al. Sustained translational repression by eIF2alpha-P mediates prion 
neurodegeneration. Nature 485, 507-511, doi:10.1038/nature11058 (2012). 
33 Stahl, S. M. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 14, 
536-546 (2009). 
 
19 
 
7. Acknowledgements 
All the work performed in this manuscript was supported by a Parkinson’s UK Project Grant: 
G1604. 
 
8. Competing Interests 
The authors declare no competing interests. 
 
9. Author contributions 
SD, PD and EJRF designed the studies. SD and EJRF wrote the main manuscript. EJRF and ADJ 
performed the experimental studies. GW performed the bioinformatics study. All authors 
reviewed the manuscript. 
 
 
  
20 
 
Candidate 
CMap 
rank 
Expression 
rank Class
dimethadione 2 0.74 anti-epileptic 
atenolol 3 0.71 cardioselective β blocker 
propranolol 5 0.69 non-selective β blocker 
clonidine 6 0.67 α2 receptor agonist
estriol 9 0.65 estrogen  
luteolin 10 0.65 flavonoid 
salbutamol 18 0.58 β2 receptor agonist 
equilin 19 0.58 horse estrogen 
ethaverine 21 0.56 L-type Ca2+ channel blocker 
torsemide 28 0.49 diuretic  
sitosterol 30 0.45 phytosterol 
levonorgestrel 33 0.42 oral contraceptive  
triflusal 34 0.42 platelet aggregation inhibitor 
trazodone 35 0.4 
5HT2A antidepressant and α1 receptor 
antagonist 
betamethasone 38 0.38 steroid
testosterone 42 0.35 primary male sex hormone 
 
 
Table 1. Candidate drugs for the up-regulation of FGF20.The candidate drugs are ranked 
based on the expression levels across the 1261 drugs in the CMap database. The relative 
expression rank of FGF20 in the individual CMap expression profiles are shown in the third 
column. The remaining 26 drugs within the top 42 were dropped from further analysis due 
to their inability for blood-brain barrier penetration and having anticipated contraindications 
either when administered chronically or with other medications frequently used by people 
with Parkinson’s disease (see Supplementary Table S1 online). 
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Candidate FGF20 fold 
increase  
SEM P value
dimethadione 4.40 0.87 0.0095 **
trazodone 2.68 0.23 0.0024 ** 
salbutamol 2.69 0.13 0.0002 *** 
atenolol 2.92 0.49 0.013 * 
propranolol 4.29 0.50 0.002 ** 
levonorgestrol 3.38 1.03 0.067
sitosterol 2.19 0.93 0.189 
clonidine 2.99 0.71 0.013 * 
luteolin 2.06 0.32 0.019 * 
torsemide 3.92 1.20 0.036 *
estriol 2.09 0.41 0.05 
triflusal 3.72 0.78 0.003 ** 
ethaverine 3.65 0.66 0.013 * 
betamethasone 2.29 0.81 0.08 
testosterone 2.57 0.48 0.016 *
equilin 2.39 0.76 0.16 
 
 
Table 2. FGF20 levels following 10 µM drug treatment in MCF-7 cells. Drugs in bold were 
taken forward into ventral mesencephalic primary culture studies. P value obtained by 
Student’s t-test analysis between drug treatment and individual vehicle controls. *, ** and 
*** are P values < 0.05, < 0.01 and < 0.001, respectively.  
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Figure Legends 
 
Figure 1. FGF20 production in ventral mesencephalic cultures following 24h incubation with 
candidate drug (@10 µM). Data are mean ± SEM. n = 3 litters per treatment. *P < 0.05; **P < 
0.01 versus vehicle treatment (ANOVA with Dunnett's post hoc test).  
 
Figure 2. Quantification by ELISA of FGF20 production in the ventral mesencephalon (vm) 
and striatum of adult male rats dosed for 7 days with dimethadione (A), trazodone (B), 
salbutamol (C), triflusal (D) or respective vehicle (0=saline). Data are mean ± SEM. n = 5 per 
dose. *P < 0.05; **P < 0.01 versus vehicle (ANOVA with Dunnett's post hoc test).  
 
Figure 3. Neuroprotective effects of salbutamol (50 mg/kg, twice-daily for 9 days) or triflusal 
(10 mg/kg, once-daily for 9 days) in unilaterally 6-OHDA-lesioned rats. A and C) 
Photomicrographs displaying the TH-positive SNc cells within the lesioned (left) and intact 
sides of drug and respective vehicle-treated controls. Quantification of SNc cells reveals 
significant protection in rats treated with salbutamol (B) or triflusal (D). *P < 0.05; **P < 0.01 
(Student’s t-test). Data are mean ± SEM. n = 10 for all groups except triflusal (n = 8).  
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